Together, our results demonstrate that CDK7 inhibition can significantly suppress the inflammation of RA via blockage of NF‐κB signalling pathway activation and IL‐1β/IL‐6 secretion, indicating that CDK7 may be an attractive target for RA therapies in the future. Here, IL1B is linked to rheumatoid arthritis.